LUMO
Lumos Pharma, Inc.
2.97
USD
This page is just a preview of the data found in TrendSpider’s full version
Lumos Pharma, Inc. stock is down -11.08% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 46.15% of the previous 12 December’s closed higher than November. 100% of analysts rate it a buy.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren.
